7DHS
Crystal Structure Analysis of the BRD4
7DHS の概要
| エントリーDOI | 10.2210/pdb7dhs/pdb |
| 分子名称 | Bromodomain-containing protein 4, 6-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1R)-1-phenylethyl]benzo[cd]indol-2-one (3 entities in total) |
| 機能のキーワード | brd4, bromodomain, structural protein |
| 由来する生物種 | Homo sapiens (Human) |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 34271.51 |
| 構造登録者 | |
| 主引用文献 | Wu, T.B.,Xiang, Q.P.,Wang, C.,Wu, C.,Zhang, C.,Zhang, M.F.,Liu, Z.X.,Zhang, Y.,Xiao, L.J.,Xu, Y. Y06014 is a selective BET inhibitor for the treatment of prostate cancer. Acta Pharmacol.Sin., 42:2120-2131, 2021 Cited by PubMed Abstract: Bromodomain and extra-terminal proteins (BETs) are potential targets for the therapeutic treatment of prostate cancer (PC). Herein, we report the design, the synthesis, and a structure-activity relationship study of 6-(3,5-dimethylisoxazol-4-yl)benzo[cd]indol-2(1H)-one derivative as novel selective BET inhibitors. One representative compound, 19 (Y06014), bound to BRD4(1) in the low micromolar range and demonstrated high selectivity for BRD4(1) over other non-BET bromodomain-containing proteins. This molecule also potently inhibited cell growth, colony formation, and mRNA expression of AR-regulated genes in PC cell lines. Y06014 also shows stronger activity than the second-generation antiandrogen enzalutamide. Y06014 may serve as a new small molecule probe for further validation of BET as a molecular target for PC drug development. PubMed: 33654218DOI: 10.1038/s41401-021-00614-7 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.76 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






